BioCentury
ARTICLE | Clinical News

Micromet AG preclinical data

July 7, 2003 7:00 AM UTC

Researchers published in the Journal of Immunology that MT103 treatment reduced tumor growth compared to control in a mouse model of lymphoma (p<0.05). The compound also prolonged survival in a dose-d...